In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer

Sung Gwe Ahn, Seung Ah Lee, Hak Woo Lee, Hak Min Lee, Joon Jeong

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: In vitro chemotherapy response assays are not widely accepted in making decisions regarding cytotoxic drugs. To evaluate the usefulness of chemotherapy response assays in breast cancer, we compared the chemotherapy response assay results according to subtypes. Human epidermal growth factor receptor-2 and Ki67 associated with chemosensitivity were also analyzed. Methods: Four hundred and ninety-six patients were enrolled, and chemotherapy response assays based on adenosine triphosphate were performed in 500 tumors. Patients were classified as five subtypes: luminal A, luminal B/human epidermal growth factor receptor-2 negative, luminal B/human epidermal growth factor receptor-2 positive, human epidermal growth factor receptor-2 and triple negative. The cell death rate for various drugs was calculated. Results: The mean cell death rate of the luminal A subtype was the lowest, and the mean cell death rates of the human epidermal growth factor receptor-2 and triple-negative subtypes were the highest for all tested drugs, except 5-fluorouracil and methotrexate. The cell death rate differed significantly among the subtypes in the types of drugs (doxorubicin, epirubicin, paclitaxel, docetaxel, gemcitabine, vinorelbine and cisplatin). In triple-negative tumors, the mean cell death rate of cisplatin was the highest among the tested drugs, and which was not observed in the other subtypes. Human epidermal growth factor receptor-2 positive tumors are associated with higher cell death rates for anthracyclines. High Ki67 expression (a cutoff of 14%) was associated with a high response in several tested drugs including epirubicin, paclitaxel, docetaxel, gemcitabine, vinorelbine and cisplatin. Conclusions: Our findings suggest that in vitro chemoresponse assays for breast tumors could effectively reflect the tumor response to chemotherapies observed in neoadjuvant settings.

Original languageEnglish
Article numberhyu057
Pages (from-to)624-631
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume44
Issue number7
DOIs
Publication statusPublished - 2014 Jul

Fingerprint

Cell Death
docetaxel
Breast Neoplasms
gemcitabine
Mortality
Drug Therapy
Pharmaceutical Preparations
Cisplatin
Epirubicin
Paclitaxel
Neoplasms
Anthracyclines
Methotrexate
Fluorouracil
Doxorubicin
human ERBB2 protein
In Vitro Techniques
Decision Making
Adenosine Triphosphate
vinorelbine

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Ahn, Sung Gwe ; Lee, Seung Ah ; Lee, Hak Woo ; Lee, Hak Min ; Jeong, Joon. / In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer. In: Japanese Journal of Clinical Oncology. 2014 ; Vol. 44, No. 7. pp. 624-631.
@article{eeb2fdd71adc40db8a267d23bd7348a8,
title = "In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer",
abstract = "Objective: In vitro chemotherapy response assays are not widely accepted in making decisions regarding cytotoxic drugs. To evaluate the usefulness of chemotherapy response assays in breast cancer, we compared the chemotherapy response assay results according to subtypes. Human epidermal growth factor receptor-2 and Ki67 associated with chemosensitivity were also analyzed. Methods: Four hundred and ninety-six patients were enrolled, and chemotherapy response assays based on adenosine triphosphate were performed in 500 tumors. Patients were classified as five subtypes: luminal A, luminal B/human epidermal growth factor receptor-2 negative, luminal B/human epidermal growth factor receptor-2 positive, human epidermal growth factor receptor-2 and triple negative. The cell death rate for various drugs was calculated. Results: The mean cell death rate of the luminal A subtype was the lowest, and the mean cell death rates of the human epidermal growth factor receptor-2 and triple-negative subtypes were the highest for all tested drugs, except 5-fluorouracil and methotrexate. The cell death rate differed significantly among the subtypes in the types of drugs (doxorubicin, epirubicin, paclitaxel, docetaxel, gemcitabine, vinorelbine and cisplatin). In triple-negative tumors, the mean cell death rate of cisplatin was the highest among the tested drugs, and which was not observed in the other subtypes. Human epidermal growth factor receptor-2 positive tumors are associated with higher cell death rates for anthracyclines. High Ki67 expression (a cutoff of 14{\%}) was associated with a high response in several tested drugs including epirubicin, paclitaxel, docetaxel, gemcitabine, vinorelbine and cisplatin. Conclusions: Our findings suggest that in vitro chemoresponse assays for breast tumors could effectively reflect the tumor response to chemotherapies observed in neoadjuvant settings.",
author = "Ahn, {Sung Gwe} and Lee, {Seung Ah} and Lee, {Hak Woo} and Lee, {Hak Min} and Joon Jeong",
year = "2014",
month = "7",
doi = "10.1093/jjco/hyu057",
language = "English",
volume = "44",
pages = "624--631",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "7",

}

In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer. / Ahn, Sung Gwe; Lee, Seung Ah; Lee, Hak Woo; Lee, Hak Min; Jeong, Joon.

In: Japanese Journal of Clinical Oncology, Vol. 44, No. 7, hyu057, 07.2014, p. 624-631.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer

AU - Ahn, Sung Gwe

AU - Lee, Seung Ah

AU - Lee, Hak Woo

AU - Lee, Hak Min

AU - Jeong, Joon

PY - 2014/7

Y1 - 2014/7

N2 - Objective: In vitro chemotherapy response assays are not widely accepted in making decisions regarding cytotoxic drugs. To evaluate the usefulness of chemotherapy response assays in breast cancer, we compared the chemotherapy response assay results according to subtypes. Human epidermal growth factor receptor-2 and Ki67 associated with chemosensitivity were also analyzed. Methods: Four hundred and ninety-six patients were enrolled, and chemotherapy response assays based on adenosine triphosphate were performed in 500 tumors. Patients were classified as five subtypes: luminal A, luminal B/human epidermal growth factor receptor-2 negative, luminal B/human epidermal growth factor receptor-2 positive, human epidermal growth factor receptor-2 and triple negative. The cell death rate for various drugs was calculated. Results: The mean cell death rate of the luminal A subtype was the lowest, and the mean cell death rates of the human epidermal growth factor receptor-2 and triple-negative subtypes were the highest for all tested drugs, except 5-fluorouracil and methotrexate. The cell death rate differed significantly among the subtypes in the types of drugs (doxorubicin, epirubicin, paclitaxel, docetaxel, gemcitabine, vinorelbine and cisplatin). In triple-negative tumors, the mean cell death rate of cisplatin was the highest among the tested drugs, and which was not observed in the other subtypes. Human epidermal growth factor receptor-2 positive tumors are associated with higher cell death rates for anthracyclines. High Ki67 expression (a cutoff of 14%) was associated with a high response in several tested drugs including epirubicin, paclitaxel, docetaxel, gemcitabine, vinorelbine and cisplatin. Conclusions: Our findings suggest that in vitro chemoresponse assays for breast tumors could effectively reflect the tumor response to chemotherapies observed in neoadjuvant settings.

AB - Objective: In vitro chemotherapy response assays are not widely accepted in making decisions regarding cytotoxic drugs. To evaluate the usefulness of chemotherapy response assays in breast cancer, we compared the chemotherapy response assay results according to subtypes. Human epidermal growth factor receptor-2 and Ki67 associated with chemosensitivity were also analyzed. Methods: Four hundred and ninety-six patients were enrolled, and chemotherapy response assays based on adenosine triphosphate were performed in 500 tumors. Patients were classified as five subtypes: luminal A, luminal B/human epidermal growth factor receptor-2 negative, luminal B/human epidermal growth factor receptor-2 positive, human epidermal growth factor receptor-2 and triple negative. The cell death rate for various drugs was calculated. Results: The mean cell death rate of the luminal A subtype was the lowest, and the mean cell death rates of the human epidermal growth factor receptor-2 and triple-negative subtypes were the highest for all tested drugs, except 5-fluorouracil and methotrexate. The cell death rate differed significantly among the subtypes in the types of drugs (doxorubicin, epirubicin, paclitaxel, docetaxel, gemcitabine, vinorelbine and cisplatin). In triple-negative tumors, the mean cell death rate of cisplatin was the highest among the tested drugs, and which was not observed in the other subtypes. Human epidermal growth factor receptor-2 positive tumors are associated with higher cell death rates for anthracyclines. High Ki67 expression (a cutoff of 14%) was associated with a high response in several tested drugs including epirubicin, paclitaxel, docetaxel, gemcitabine, vinorelbine and cisplatin. Conclusions: Our findings suggest that in vitro chemoresponse assays for breast tumors could effectively reflect the tumor response to chemotherapies observed in neoadjuvant settings.

UR - http://www.scopus.com/inward/record.url?scp=84903377504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903377504&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyu057

DO - 10.1093/jjco/hyu057

M3 - Article

C2 - 24803548

AN - SCOPUS:84903377504

VL - 44

SP - 624

EP - 631

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 7

M1 - hyu057

ER -